Deciphering the Adaptive Immune System
The adaptive immune system holds the blueprint for combating disease, yet its extreme diversity has historically hindered biotechnology R&D.
The Clonotype Overlap Barrier
A fundamental biological hurdle has prevented the effective use of the adaptive immune repertoire in developing precision drugs and predictive biomarkers. Because diverse individuals share a remarkably low number of overlapping B-cell and T-cell receptor (BCR/TCR) clonotypes, traditional sequence-matching methods fail to identify actionable, generalizable therapeutic targets across patient populations. Relying on rare, identical sequence matches masks the immune system's vast intelligence behind highly individualized data, leading to suboptimal target selection and high clinical attrition.
Generalizing Immunity via Paratope Clusters
Our AI platform solves this "donor sharing problem." Instead of relying on restrictive clonotype matching, our technology generalizes individual immune responses by identifying "public" and highly shared paratope clusters. By analyzing antigen-binding regions (paratopes), our computational engine accurately groups distinct immune receptors that target the same antigen even when patients have a low sequence overlap, translating complex, individualized biology into precise, actionable data.
Epitope Specficity of Paratope Clusters
By analyzing the structural and functional features of antigen-binding regions (paratopes), our computational engine accurately groups distinct immune receptors that target the exact same antigen even when patients have a low sequence overlap, translating complex, individualized biology into precise, actionable data. Crucially, we have empirically demonstrated that the public clusters generated by MyImmune’s platform possess exceptionally high epitope specificity (>95% cluster purity).
Unlocking New Applications:
Our Research-Use-Only (RUO) platform empowers your R&D with entirely new applications:
Therapeutic Antibodies & TILs
Identify potent, naturally selected therapeutic antibodies and tumor-infiltrating lymphocytes (TILs) directly from patient-derived immune patterns.
Vaccine Development
Map validated human epitope landscapes to engineer stable, highly immunogenic antigens for prophylactic and therapeutic vaccines.
Autoimmunity Targets
Identify shared autoantibody-epitope binding sites across broad patient populations to uncover novel disease mechanisms.
Precision Oncology
Elucidate neoantigen response patterns in cancer patient populations to inform targeted immunotherapies and combination trial designs.